HFA Icon

Ackman Adds Exposure As Valeant Responds to Citron

HFA Padded
Mark Melin
Published on
Updated on
Sign up for our E-mail List and Get FREE Access to Exclusive Investment E-books and More!

Valeant stock rebounded in the afternoon, aided in part by an announcement by the firm categorizing Citron’s research as erroneous and an announcement by one of their largest shareholders, William Ackman, that he had bought the stock while blood was on the street.

Ackman gets behind his Valeant exposure after a rough day

As Valeant stock was trading down at $88.58 around at 1:35 PM Eastern Time, and Pershing Square’s loss on the day was just over $1.1 billion, William Ackman might have smelled blood on the street. Ackman was reported to have purchased an additional 2 million shares Wednesday, bringing his total exposure up to 21.5 million shares.

It is unknown when exactly Ackman...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article
Already a member? Log in here
HFA Padded

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.